Literature DB >> 7528330

Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library.

A Lieber1, M Strauss.   

Abstract

Inactivation of gene expression by antisense mechanisms in general and by ribozymes in particular is a powerful technique for studying the function of a gene product. We have designed a strategy for expression of ribozymes, for selection of accessible cleavage sites in target RNAs, and for isolation of ribozymes from a library of random sequences flanking the unique sequence of a hammerhead. The expression cassette for ribozyme genes is based on adenovirus-associated RNA. Alternatively, we used polymerase III or the T7 phage transcription machinery. The ribozyme sequences are positioned in the center of a stable stem-loop structure, allowing for a correctly folded ribozyme region within the expressed RNA. A library of ribozyme genes with random sequences of 13 nucleotides on both sides of the hammerhead was generated. As an example, ribozymes which are specific for seven sites within the mRNA or nuclear RNA of human growth hormone were selected and identified. Sequencing of ribozyme genes reamplified from the library confirmed not only the predicted cleavage sites but also the presence of different ribozyme variants in the library. In a test of the ribozyme variants for repression of growth hormone synthesis in a cellular assay, the strongest effect (more than 99% inhibition) was found for the variant with the shortest stretch of complementarity (7 and 8 nucleotides on either side) to the target RNA. This basic strategy seems to be applicable to the selection of suitable target sites and to the isolation of corresponding ribozymes for any mRNA of interest.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7528330      PMCID: PMC232008          DOI: 10.1128/MCB.15.1.540

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  47 in total

1.  High level gene expression in mammalian cells by a nuclear T7-phase RNA polymerase.

Authors:  A Lieber; U Kiessling; M Strauss
Journal:  Nucleic Acids Res       Date:  1989-11-11       Impact factor: 16.971

2.  The chemistry of self-splicing RNA and RNA enzymes.

Authors:  T R Cech
Journal:  Science       Date:  1987-06-19       Impact factor: 47.728

3.  Simple RNA enzymes with new and highly specific endoribonuclease activities.

Authors:  J Haseloff; W L Gerlach
Journal:  Nature       Date:  1988-08-18       Impact factor: 49.962

Review 4.  Ribonuclease P: an enzyme with a catalytic RNA subunit.

Authors:  S Altman
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1989

5.  A small catalytic oligoribonucleotide.

Authors:  O C Uhlenbeck
Journal:  Nature       Date:  1987 Aug 13-19       Impact factor: 49.962

6.  Improved hybridization conditions for DNA 'fingerprints' probed with M13.

Authors:  D F Westneat; W A Noon; H K Reeve; C F Aquadro
Journal:  Nucleic Acids Res       Date:  1988-05-11       Impact factor: 16.971

7.  Mapping of transcriptional start and capping points by a modified 5' RACE technique.

Authors:  S Bähring; V Sandig; A Lieber; M Strauss
Journal:  Biotechniques       Date:  1994-05       Impact factor: 1.993

8.  Specific gene suppression by engineered ribozymes in monkey cells.

Authors:  F H Cameron; P A Jennings
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

9.  Immortalized differentiated hepatocyte lines derived from transgenic mice harboring SV40 T-antigen genes.

Authors:  D Paul; M Höhne; C Pinkert; A Piasecki; E Ummelmann; R L Brinster
Journal:  Exp Cell Res       Date:  1988-04       Impact factor: 3.905

10.  Ribozyme mediated destruction of RNA in vivo.

Authors:  M Cotten; M L Birnstiel
Journal:  EMBO J       Date:  1989-12-01       Impact factor: 11.598

View more
  31 in total

1.  Identifying ribozyme-accessible sites using NUH triplet-targeting gapmers.

Authors:  A A Mir; T J Lockett; P Hendry
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

2.  RNA aptamers as effective protein antagonists in a multicellular organism.

Authors:  H Shi; B E Hoffman; J T Lis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

3.  Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes.

Authors:  M Amarzguioui; G Brede; E Babaie; M Grotli; B Sproat; H Prydz
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

4.  Small, efficient hammerhead ribozymes.

Authors:  M J McCall; P Hendry; A A Mir; J Conaty; G Brown; T J Lockett
Journal:  Mol Biotechnol       Date:  2000-01       Impact factor: 2.695

5.  Selection of targets and the most efficient hairpin ribozymes for inactivation of mRNAs using a self-cleaving RNA library.

Authors:  A Barroso-DelJesus; A Berzal-Herranz
Journal:  EMBO Rep       Date:  2001-11-21       Impact factor: 8.807

6.  A selection system for identifying accessible sites in target RNAs.

Authors:  W H Pan; H F Devlin; C Kelley; H C Isom; G A Clawson
Journal:  RNA       Date:  2001-04       Impact factor: 4.942

7.  A small nucleolar RNA:ribozyme hybrid cleaves a nucleolar RNA target in vivo with near-perfect efficiency.

Authors:  D A Samarsky; G Ferbeyre; E Bertrand; R H Singer; R Cedergren; M J Fournier
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

8.  Oligonucleotide-directed site-specific integration of high complexity libraries into ssDNA templates.

Authors:  M B Hale; G P Nolan; R Wolkowicz
Journal:  Nucleic Acids Res       Date:  2004-01-29       Impact factor: 16.971

Review 9.  Bottlenecks in development of retinal therapeutic post-transcriptional gene silencing agents.

Authors:  Jack M Sullivan; Edwin H Yau; R Thomas Taggart; Mark C Butler; Tiffany A Kolniak
Journal:  Vision Res       Date:  2007-10-31       Impact factor: 1.886

10.  A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines.

Authors:  M Y Chang; S J Won; H S Liu
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.